OncoMatch/Clinical Trials/NCT07337876
Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy
Is NCT07337876 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for rectal cancer.
This study is testing whether radiation delivered with MRI guidance using a so-called MR-linac in distal rectal cancer can result in a high rate of organ preservation. Patients will receive radiotherapy together with standard chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Performance status
WHO/ECOG 0–1
Prior therapy
Cannot have received: antineoplastic therapy
Prior antineoplastic therapy for rectal cancer
Cannot have received: radiotherapy
Prior radiotherapy of the pelvic region
Lab requirements
Blood counts
adequate hematological function parameters
Kidney function
adequate renal function parameters
Liver function
adequate hepatic function parameters
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07337876 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages